Clinical impact of LixiLan, a fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on oral agents: LixiLan-O trialJ. Rosenstock,R. Aronson,M. Hanefeld, P. Piatti, P. Serusclat,X. Cheng, T. Zhou,E. Niemoeller, E. Souhami,G. Grunberger, M. DaviesDIABETOLOGIA（2016）引用 0|浏览10暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
